Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IP 001

Next Previous
X
Search
Drug Profile

IP 001

Alternative Names: GC - Immunophotonics; inCVAX-GC; inCVAX-IP001; inCVAX-N-dihydro-galacto-chitosan; IP-001

Latest Information Update: 14 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunophotonics
  • Developer Immunophotonics; Swiss Group for Clinical Cancer Research
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Antigen presenting cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • No development reported Breast cancer

Most Recent Events

  • 07 Oct 2024 Phase-I/II clinical trials in Liver metastases (Second-line therapy or greater) in Netherlands (Intratumoural) (NCT06630624)
  • 29 Jul 2024 University of Louisville plans a phase II trial for Liver cancer (Adjuvant therapy) in July 2024 (NCT06526338)
  • 15 Dec 2022 Phase-I/II clinical trials in Colorectal cancer (Second-line therapy or greater, Late-stage disease) in Switzerland, France, United Kingdom, Germany (Intratumoural) (ISRCTN16103145)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top